SynthesisBMC medical imaging2025
Investigating the significance of SPECT/CT-SUV for monitoring
Synthesis in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of interim post-treatment SPECT/CT following lutetium-177 (177Lu)-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- The predictive role of [European journal of nuclear medicine and molecular imaging · 2026Article
- Impact of partial volume correction on radiomics reproducibility in theranostic SPECT/CT imaging.Medical physics · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuantitative molecular imaging via single-photon emission computed tomography-derived standardised uptake value (SPECT/CT-SUV) is used to assess the response of metastatic castration-resistant prostate cancer (mCRPC) patients to targeted radionuclide therapy (TRT) with [
methodsA systematic review was conducted in accordance with the PRISMA guidelines. The MEDLINE/PubMed databases were searched from January 2016 to July 2024 to identify relevant articles. The inclusion criterion was the use of quantitative SPECT/CT-SUV during [
resultsA total of five studies were included in this systematic review (two prospective studies and three retrospective studies). The sample sizes of the studies ranged from 6 to 73 patients. The highest number of lesions analysed was 144. Three studies reported the SPECT/CT-SUV following cycle 1, and only one study reported the correlation with pretherapy PET/CT (r = 0.9, p = 0.005). SPECT/CT-SUV changes between the first two to three cycles were reported in one study. None of the studies reported the SPECT/CT-SUV for normal organs. One study reported correlations between SPECT/CT-derived SUV and PET/CT-derived SUV in target and nontarget tissues.
conclusionQuantitative SPECT/CT-SUV can be used to predict responses to subsequent PSMA-TRT cycles. Disease burden and tumour heterogeneity are the leading causes of TRT individualisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.